ReviewCurrent neurology and neuroscience reports2008
Advances in the pathogenesis and treatment of patients with stiff person syndrome.
Review in Current neurology and neuroscience reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 59 citations in OpenAlex.
- Article
- A Pediatric Case of Stiff-Person Syndrome: Presentation and Comparative Analysis.Journal of orthopaedic case reports · 2026Article
- Polyclonal glycine receptor aAbs: a challenge for personalized epitope characterization.Frontiers in molecular neuroscience · 2026Article
- Binding patterns of glycine receptor autoantibodies are related to clinical syndromes.Acta neuropathologica communications · 2025Article
- Proposing Bromo-Epi-Androsterone (BEA) for Stiff Person Syndrome (SPS).Microorganisms · 2025Article
- Chimeric antigen receptor T-cell therapy for stiff-person syndrome: bridging innovation and clinical challenges in neuroimmunology.Therapeutic advances in neurological disorders · 2025Review
- Emergent Anesthetic Management in a Patient Recently Diagnosed With Stiff Person Syndrome.Cureus · 2024Article
- A new perspective on the autophagic and non-autophagic functions of the GABARAP protein family: a potential therapeutic target for human diseases.Molecular and cellular biochemistry · 2024Review
- Prevalence, Clinical Profiles, and Prognosis of Stiff-Person Syndrome in a Japanese Nationwide Survey.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions.Therapeutic advances in neurological disorders · 2021Review
- Cerebrospinal Fluid Findings of 36 Adult Patients with Autism Spectrum Disorder.Brain sciences · 2020Article
- Stiff-Person Syndrome: A Case Report and Review of the Literature.The British and Irish orthoptic journal · 2019Article
- Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder.BMC neurology · 2019Article
- Stiff person case misdiagnosed as conversion disorder: A case report.Caspian journal of internal medicine · 2017Article
- Anti-glutamic acid decarboxylase antibody positive neurological syndromes.Neurosciences (Riyadh, Saudi Arabia) · 2016Review
- Neuronal autoantigens--pathogenesis, associated disorders and antibody testing.Nature reviews. Neurology · 2012Review
- Article
- Anti-glutamic Acid decarboxylase antibody-associated ataxia as an extrahepatic autoimmune manifestation of hepatitis C infection: a case report.Case reports in neurological medicine · 2011Article
- Autoantibodies to glutamic acid decarboxylase in patients with epilepsy are associated with low cortical GABA levels.Epilepsia · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in the clinical diagnosis, prognosis, pathogenesis, and therapies for stiff person syndrome (SPS), based on observations in more than 50 consecutive patients, are presented. The syndrome varies from mild to severe, but if untreated it can be progressive and disabling. SPS remains a largely underdiagnosed condition. Anti-glutamic acid decarboxylase (GAD) antibodies provide an excellent diagnostic marker, but their role in disease pathogenesis is uncertain. Research focused on identifying new autoantigens has provided evidence that gamma-aminobutyric acid (GABA)(A) receptor-associated protein (GABARAP), a 14-kD protein localized at the postsynaptic regions of GABAergic synapses, is a new antigenic target. In up to 65% of SPS patients, there are circulating anti-GABARAP antibodies that inhibit the GABA(A) receptor expression on GABAergic neurons. This review examines the diagnostic criteria for SPS, SPS variants, common errors in diagnosis, and a step-by-step therapeutic approach, including new advances in therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.